Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


18.06.2018

1 AJR Am J Roentgenol
2 Anticancer Res
1 BJU Int
1 Cancer Res
2 Eur Urol
2 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Clin Oncol
2 J Urol
2 Lancet Oncol
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Prostate
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. NIU XK, Chen XH, Chen ZF, Chen L, et al
    Diagnostic Performance of Biparametric MRI for Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2018 Jun 12:1-10. doi: 10.2214/AJR.17.18946.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. VARGA L, Koszo RL, Fodor E, Cserhati A, et al
    Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy.
    Anticancer Res. 2018;38:3699-3705.
    PubMed     Text format     Abstract available

  3. TRIGGIANI L, Colosini A, Buglione M, Pasinetti N, et al
    Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro Study.
    Anticancer Res. 2018;38:3487-3492.
    PubMed     Text format     Abstract available


    BJU Int

  4. ELLIOTT D, Hamdy FC, Leslie TA, Rosario D, et al
    Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation versus radical prostatectomy for unilateral localised prostate cancer.
    BJU Int. 2018 Jun 11. doi: 10.1111/bju.14432.
    PubMed     Text format     Abstract available


    Cancer Res

  5. LIU J, Chen G, Liu Z, Liu S, et al
    Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3226.
    PubMed     Text format     Abstract available


    Eur Urol

  6. NAIR R, Porpiglia F, Zargar H
    Re: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis.
    Eur Urol. 2018 Jun 6. pii: S0302-2838(18)30418.
    PubMed     Text format    

  7. AMINSHARIFI A, Polascik TJ
    Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.
    Eur Urol. 2018 Jun 8. pii: S0302-2838(18)30420.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  8. SPRATT DE
    Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;101:513-515.
    PubMed     Text format    

  9. BRYANT AK, Kader AK, McKay RR, Einck JP, et al
    Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Apr 17. pii: S0360-3016(18)30680.
    PubMed     Text format     Abstract available


    Int J Urol

  10. SAKAMOTO S
    Editorial Comment to Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018;25:531-532.
    PubMed     Text format    


    J Clin Oncol

  11. REN C, Han C, Wang D, Chen H, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?
    J Clin Oncol. 2018 Jun 12:JCO2018781401. doi: 10.1200/JCO.2018.78.1401.
    PubMed     Text format    


    J Urol

  12. MARZOUK K, Assel M, Ehdaie B, Vickers A, et al
    Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort.
    J Urol. 2018 Jun 7. pii: S0022-5347(18)43349-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  13. LEPPERT JT, Asch SM, Bergman J
    Ethical Pitfalls When Estimating Life Expectancy For Patients with Prostate Cancer.
    J Urol. 2018 Jun 6. pii: S0022-5347(18)43328-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format    


    Lancet Oncol

  14. CLARKE N, Wiechno P, Alekseev B, Sala N, et al
    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30365.
    PubMed     Text format     Abstract available

  15. ANTONARAKIS ES
    Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30409.
    PubMed     Text format    


    Oncol Rep

  16. TANG Q, Ma J, Sun J, Yang L, et al
    Genistein and AG1024 synergistically increase the radiosensitivity of prostate cancer cells.
    Oncol Rep. 2018 May 30. doi: 10.3892/or.2018.6468.
    PubMed     Text format     Abstract available


    PLoS One

  17. SMITH DP, Calopedos R, Bang A, Yu XQ, et al
    Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data.
    PLoS One. 2018;13:e0198679.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  18. NAVARRO HI, Goldstein AS
    HoxB13 mediates AR-V7 activity in prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Jun 11. pii: 1808196115.
    PubMed     Text format    


    Prostate

  19. BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
    Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
    PubMed     Text format     Abstract available

  20. CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
    A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
    PubMed     Text format     Abstract available


    Radiology

  21. JOHNSTON E, Punwani S
    Can We Improve the Reproducibility of Quantitative Multiparametric Prostate MR Imaging Metrics?
    Radiology. 2016;281:652-653.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: